RecruitingNot ApplicableNCT05227534
Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)
A Prospective Multi-canceR Early-detection and interVENTional Study in Asymptomatic Individuals: PREVENT
Sponsor
Guangzhou Burning Rock Dx Co., Ltd.
Enrollment
12,500 participants
Start Date
Jun 1, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
PREVENT is a prospective, multicenter, interventional study evaluating the performance of the OverC multi-cancer detection blood test in asymptomatic individuals with cancer risk.
Eligibility
Min Age: 40 YearsMax Age: 75 Years
Inclusion Criteria4
- Participants must be able to provide a written informed consent form
- Participants must not have received any colonoscopy, abdominal MRI/CT, low-dose CT, or chest CT within 5 years before signing the informed consent form
- Participants must be able to provide blood samples for study tests
- Participants must be between 40 and 75 years old
Exclusion Criteria13
- Individuals who have an acute infection or inflammation within 14 days prior to recruitment
- Individuals with cancer-associated clinical symptoms or suspected of cancer
- Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant
- Recipient of blood transfusion within 7 days prior to recruitment
- Individuals who have pure ground-glass opacity
- Unable to provide blood samples for the multi-cancer early detection blood test
- Individuals who are unable to tolerate standard-of-care cancer screening tests or have contraindications of standard-of-care cancer screening tests
- Individuals who have taken medication with anti-tumor effects within 30 days prior to recruitment
- Individuals who have received or are undergoing curative cancer treatment within three years prior to recruitment
- Individuals with hemorrhagic diseases
- Individuals with autoimmune diseases
- Individuals who are pregnant or lactating
- Individuals who have severe comorbidities that are not suitable for participating in the trial judged by researchers
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEOverC multi-cancer detection blood test
Blood collection for the OverC multi-cancer detection blood test and standard-of-care screening with return of results
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05227534
Related Trials
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
NCT055881411 location
Patient-Centered Assessment of Symptoms and Outcomes
NCT039526241 location
Tumor Related Epilepsy
NCT026393251 location
Improving Engagement in HIV and Cancer Care in Zimbabwe
NCT069343691 location
Study of a Support Program for Quality of Life in Chinese Cancer Patients and Survivors
NCT074543307 locations